Clovis Oncology (CLVS) to Suspend CO-101 Development Following New LEAP Results
Tweet Send to a Friend
Clovis Oncology, Inc. (Nasdaq: CLVS) announced the results from its LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
